UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000009858 |
|---|---|
| Receipt number | R000011550 |
| Scientific Title | A multicenter, open-label, single-dose study to investigate the effects of the ABCC4 (MRP4) rs3765534 G>A polymorphism on the pharmacokinetics of ceftizoxime in East Asian population |
| Date of disclosure of the study information | 2013/02/01 |
| Last modified on | 2014/08/26 11:03:41 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A multicenter, open-label, single-dose study to investigate the effects of the ABCC4 (MRP4) rs3765534 G>A polymorphism on the pharmacokinetics of ceftizoxime in East Asian population
Acronym
The effects of the ABCC4 (MRP4) rs3765534 G>A polymorphism on the pharmacokinetics of ceftizoxime in East Asian population
Scientific Title
A multicenter, open-label, single-dose study to investigate the effects of the ABCC4 (MRP4) rs3765534 G>A polymorphism on the pharmacokinetics of ceftizoxime in East Asian population
Scientific Title:Acronym
The effects of the ABCC4 (MRP4) rs3765534 G>A polymorphism on the pharmacokinetics of ceftizoxime in East Asian population
Region
| Japan | Asia(except Japan) |
Condition
Condition
Healthy volunteers
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
1)To determine whether the ABCC4 (MRP4) rs3765534 G>A polymorphism affects the pharmacokinetics of cefozolin in humans.
2)To investigate whether ethnicity (Chinese, Korean or Japanese) affects the pharmacokinetics of ceftizoxime.
Basic objectives2
PK,PD
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Explanatory
Developmental phase
Not applicable
Assessment
Primary outcomes
Pharmacokinetic parameters of ceftizoxime:
-Cmax: maximum measured serum concentration over the time span specified
-AUClast: the area under the serum concentration versus time curve, from time 0 to the last measurable concentration
-AUCinf: the area under the serum concentration versus time curve from time 0 to infinity
-t1/2: the time necessary for the serum concentration of drug to decrease by half
-Vd: the total volume of distribution
-CLtot: the total body clearance
-CLren: the renal clearance
Key secondary outcomes
Adverse events
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
A single intravenous dose of ceftizoxime sodium 0.5 g administered over 30 min
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 50 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1)Healthy male and female volunteers, age ranged 20 to 50 years (both inclusive)
2)A subject with body weight between 45 kg (inclusive) and 80 kg (inclusive) for female, and between 50 kg (inclusive) and 90 kg (inclusive) for male, and body mass index (BMI) between 17 (inclusive) and 28 (inclusivee) for both gender.
3)Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the laboratory reference ranges for the relevant laboratory tests (including the case that the investigator considers the deviation to be irrelevant for the purpose of the study)
Key exclusion criteria
1)A subject with history of allergies including study drug or any other food and drug allergies (aspirin, antibiotics, etc.), or history of clinically significant allergies
2)A subject with clinical evidence or history of hepatic (including carrier of hepatitis virus), renal, gastrointestinal, respiratory (including asthma and COPD), endocrine, neurologic, immunologic, hematologic, oncologic, psychiatric, or cardiovascular disease
3)A subject who shows a positive reaction to any one of serology tests (hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody).
4)A subject with a history of surgery (except simple appendectomy or repair of hernia)
5)A subject with history of drug abuse or positive urine drug screening test
6)A subject who has taken any prescribed medication or herbal compounds within 14 days prior to the study drug administration. In addition, a subject who has taken any over-the-counter drug or vitamin supplements within 7 days prior to the study drug administration (However, investigators can judge the subject, who has taken the medications during those periods above, eligible for the trial if all other conditions are satisfied.)
7)A subject who consumes more than 7 units of alcohol (140g) per week or unable to stop drinking throughout the study period
8)A smoker (except for whom quitted smoking prior to the drug administration for at least 3 months)
9)A subject who heavily takes caffeine or caffeine-containing products, grapefruit, grapefruit juice, grapefruit-containing products
10)A female subject who are pregnant or breast feeding
11)A female subject who does not agree to use routinely adequate contraception* from signing of informed consent throughout the duration of the study and for 30 days after the last dose of study drug despite having a childbearing potential and being sexually active with a non-sterilized male partner.
Target sample size
38
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Kyoichi Ohashi |
Organization
Oita University Faculty of Medicine
Division name
Department of Clinical Pharmacology and Therapeutics
Zip code
Address
1-1 Idaigaoka Hasama-machi, Yufu 879-5593, Japan
TEL
097-586-5952
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Tsutomu Kotegawa |
Organization
Oita University Faculty of Medicine
Division name
Department of Clinical Pharmacology and Therapeutics
Zip code
Address
1-1 Idaigaoka Hasama-machi, Yufu 879-5593, Japan
TEL
097-586-5952
Homepage URL
kotet@oita-u.ac.jp
Sponsor or person
Institute
Department of Clinical Pharmacology and Therapeutics,
Oita University Faculty of Medicine
Institute
Department
Personal name
Funding Source
Organization
Grant-in-aid from the Ministry of Health, Labour and Welfare
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
1)Clinical Pharmacolgy Research Center, Peking Union Medical College Hospital, China
2)Clinical Trials Center, Seoul National University Hospital, Korea
3)Center for Advanced Medical Innovation, Kyushu University, Fukuoka, Japan
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 02 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 12 | Month | 11 | Day |
Date of IRB
Anticipated trial start date
| 2013 | Year | 02 | Month | 01 | Day |
Last follow-up date
| 2013 | Year | 12 | Month | 17 | Day |
Date of closure to data entry
| 2014 | Year | 01 | Month | 31 | Day |
Date trial data considered complete
| 2014 | Year | 02 | Month | 28 | Day |
Date analysis concluded
| 2014 | Year | 03 | Month | 31 | Day |
Other
Other related information
Management information
Registered date
| 2013 | Year | 01 | Month | 24 | Day |
Last modified on
| 2014 | Year | 08 | Month | 26 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011550
